| 1 |
NCT02489695 |
Active, not recruiting |
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma |
- Papillary Renal Cell Carcinoma
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The efficacy of axitinib in first-line treatment of PRCC.
- The safety of axitinib in patients with PRCC (NCI CTCAE v4)
- The progression-free survival (RECIST 1.1) in each PRCC subtypes
- (and 4 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02489695 |
AXIPAP
ET14-090 |
AXIPAP |
October 2015 |
August 2018 |
January 2019 |
July 3, 2015 |
February 28, 2018 |
|
- ICO Paul Papin
Angers, France - Chu Bordeaux
Bordeaux, France - Centre Francois Baclesse
Caen, France - (and 7 more...)
|
| 2 |
NCT02495103 |
Recruiting |
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma |
- Renal Cell Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Papillary Renal Cell Carcinoma, Sporadic
|
- Drug: Vandetanib
- Drug: Metformin
- Drug: Vandetanib/Metformin
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Component: To establish the safety and maximum tolerated dose (MTD) of vandetanib and metformin when used in combination in patients with metastatic RCC.
- Phase 2 Component: To determine the overall response rate (RECIST 1.1) following treatment with the combination of vandetanib and metformin in patients with 1) advanced RCC associated with HLRCC or SDH, and 2) advanced sporadic/non-HLRCC papilla...
- Phase 1 Component: Evaluate the clinical activity of the combination of vandetanib and metformin
- (and 6 more...)
|
73 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02495103 |
150157
15-C-0157 |
|
July 8, 2015 |
May 1, 2021 |
May 1, 2022 |
July 13, 2015 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 3 |
NCT02019693 |
Recruiting |
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer |
- Papillary Renal Cell Carcinoma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Progression-free survival, overall survival, disease control rate and duration of response, tolerability
|
22 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02019693 |
140037
14-C-0037 |
|
December 20, 2013 |
January 1, 2019 |
January 1, 2019 |
December 24, 2013 |
March 12, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT00726323 |
Completed
Has Results |
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) |
|
- Drug: foretinib (formerly GSK1363089 or XL880)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0
- Disease Stabilization Rate Over Period
- Progression Free Survival (PFS)
- (and 7 more...)
|
74 |
All |
18 Years and older (Adult, Senior) |
NCT00726323 |
MET111644 |
|
June 30, 2006 |
August 18, 2010 |
August 18, 2010 |
July 31, 2008 |
December 11, 2017 |
December 11, 2017 |
- GSK Investigational Site
Greenbrae, California, United States - GSK Investigational Site
San Francisco, California, United States - GSK Investigational Site
Stanford, California, United States - (and 9 more...)
|
| 5 |
NCT02127710 |
Active, not recruiting
Has Results |
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) |
- Papillary Renal Cell Cancer
|
|
Interventional |
Phase 2 |
- AstraZeneca
- SCRI Development Innovations, LLC
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate in Efficacy Analysis Set (n = 84)
- Objective Response Rate in the Safety Analysis Set (n = 109)
- Progression Free Survival (PFS) in the Efficacy Analysis Set (n = 84)
- (and 3 more...)
|
104 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02127710 |
D5082C00002
GU 111 |
|
April 30, 2014 |
April 14, 2016 |
December 31, 2021 |
May 1, 2014 |
October 12, 2017 |
October 12, 2017 |
- Research Site
Birmingham, Alabama, United States - Research Site
Duarte, California, United States - Research Site
Palo Alto, California, United States - (and 22 more...)
|
| 6 |
NCT01688973 |
Completed |
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery |
- Recurrent Renal Cell Carcinoma
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer
- (and 2 more...)
|
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Drug: Tivantinib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate (confirmed complete response or partial response), determined according to Response Evaluation Criteria in Solid Tumors
- Frequency and severity of toxicities, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- PFS
|
65 |
All |
Child, Adult, Senior |
NCT01688973 |
NCI-2012-01641
S1107
SWOG-S1107
U10CA180888
U10CA032102 |
|
August 20, 2012 |
April 30, 2017 |
April 30, 2017 |
September 20, 2012 |
August 29, 2017 |
|
- University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, United States - University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States - The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - (and 211 more...)
|
| 7 |
NCT00601926 |
Terminated
Has Results |
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer |
|
|
Interventional |
Phase 2 |
- Paul Monk
- Genentech, Inc.
- Ohio State University Comprehensive Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) When Bevacizumab is Administered to Patients With Unresectable and/or Metastatic Papillary Renal Cell Carcinoma.
- Response Rate to Bevacizumab in This Population.
- Safety of Bevacizumab in This Population of Patients
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT00601926 |
OSU-06111
NCI-2011-03160 |
|
February 2008 |
August 2011 |
May 2013 |
January 28, 2008 |
June 15, 2015 |
February 18, 2015 |
- Ohio State University Medical Center
Columbus, Ohio, United States
|
| 8 |
NCT00541008 |
Unknown † |
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer |
|
|
Interventional |
Phase 2 |
- UNICANCER
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response rate
- Safety
- Overall survival
- (and 3 more...)
|
92 |
All |
18 Years and older (Adult, Senior) |
NCT00541008 |
CDR0000569863
FRE-FNCLCC-GEP-03-0603
EU-20761
EUDRACT-2006-003339-62
PFIZER-FRE-FNCLCC-GEP-03-0603 |
|
September 2007 |
|
|
October 8, 2007 |
August 16, 2011 |
|
- Centre Paul Papin
Angers, France - Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France - Hopital Saint Andre
Bordeaux, France - (and 19 more...)
|
| 9 |
NCT02761057 |
Recruiting |
Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer |
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7
- Type 1 Papillary Renal Cell Carcinoma
- Type 2 Papillary Renal Cell Carcinoma
|
- Drug: Cabozantinib S-malate
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Response rate (RR)
- Overall survival (OS)
- Incidence of toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
|
180 |
All |
Child, Adult, Senior |
NCT02761057 |
NCI-2015-01707
S1500
U10CA180888 |
|
April 5, 2016 |
March 1, 2020 |
|
May 4, 2016 |
April 17, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 537 more...)
|
| 10 |
NCT00459875 |
Completed
Has Results |
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer |
|
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Objective Response Rate as Measured by RECIST
|
24 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00459875 |
07-019
P30CA008748
MSKCC-07019 |
|
March 2007 |
November 2010 |
November 2010 |
April 13, 2007 |
November 26, 2015 |
November 26, 2015 |
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
| 11 |
NCT03091192 |
Recruiting |
Savolitinib vs. Sunitinib in MET-driven PRCC |
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- (and 5 more...)
|
- Drug: Savolitinib
- Drug: Sunitinib
|
Interventional |
Phase 3 |
- AstraZeneca
- Hutchinson MediPharma (HMP)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Objective Response Rate (ORR)
- (and 6 more...)
|
180 |
All |
18 Years to 130 Years (Adult, Senior) |
NCT03091192 |
D5082C00003 |
|
July 25, 2017 |
March 31, 2020 |
June 30, 2021 |
March 27, 2017 |
March 30, 2018 |
|
- Research Site
La Jolla, California, United States - Research Site
Saint Petersburg, Florida, United States - Research Site
Atlanta, Georgia, United States - (and 73 more...)
|
| 12 |
NCT01727089 |
Completed |
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer |
- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage IV Renal Cell Cancer
- (and 2 more...)
|
- Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Progression-free survival (PFS)
- Incidence of adverse events (AE) and toxicity of study treatment
- Response rate assessed by RECIST
|
88 |
All |
18 Years and older (Adult, Senior) |
NCT01727089 |
NCI-2012-02206
PHII-121
PhII-121
9144
N01CM00038
N01CM00039
N01CM00071
N01CM00099
P30CA033572 |
|
November 1, 2012 |
August 8, 2017 |
August 8, 2017 |
November 15, 2012 |
September 6, 2017 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 27 more...)
|
| 13 |
NCT03319628 |
Recruiting |
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b |
- Platinum Resistant Ovarian Cancer
- Non-Small Cell Lung Cancer, Non-squamous
- Papillary Renal Cell Carcinoma
- (and 2 more...)
|
|
Interventional |
Phase 1 |
- Mersana Therapeutics
- Novella Clinical
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose or recommended Phase 2 dose
- Time of maximum observed concentration of XMT-1536
- Maximum concentration of XMT-1536
- (and 3 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03319628 |
XMT-1536-1 |
|
December 12, 2017 |
December 1, 2018 |
June 30, 2019 |
October 24, 2017 |
January 31, 2018 |
|
- Dana Farber Cancer Insititute
Boston, Massachusetts, United States - Stephenson Cancer Centre-University of Oklahoma
Oklahoma City, Oklahoma, United States - University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania, United States - (and 3 more...)
|
| 14 |
NCT03177239 |
Recruiting |
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) |
- Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma Type 1
- Papillary Renal Cell Carcinoma Type 2
- (and 3 more...)
|
- Drug: Nivolumab
- Drug: Ipilimumab
|
Interventional |
Phase 2 |
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The objective tumour response rate, as assessed by RECIST1.1
- Duration of objective tumour response, as assessed by RECIST1.1
- Progression-free survival (PFS), as assessed by RECIST1.1
- (and 5 more...)
|
85 |
All |
18 Years and older (Adult, Senior) |
NCT03177239 |
ANZUP 1602 |
UNISoN |
October 19, 2017 |
December 2021 |
December 2022 |
June 6, 2017 |
April 4, 2018 |
|
- Border Medical Oncology
Albury, New South Wales, Australia - Campbelltown Hospital
Campbelltown, New South Wales, Australia - Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - (and 12 more...)
|
| 15 |
NCT00098618 |
Terminated |
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer |
- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- (and 2 more...)
|
- Drug: sorafenib tosylate
- Biological: recombinant interferon alfa
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (CR+PR) using RECIST criteria
- Grade 3+ toxicities assessed using NCI CTCAE version 3.0
- Progression-free survival
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT00098618 |
NCI-2012-02638
6258-04-9R0
NCI-6553
CDR0000398171
U01CA099118 |
|
October 2004 |
January 2006 |
|
December 8, 2004 |
July 2, 2013 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 16 |
NCT01524926 |
Active, not recruiting |
CREATE: Cross-tumoral Phase 2 With Crizotinib |
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma
- Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
- Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1
- (and 3 more...)
|
- Drug: Crizotinib (PF-02341066)
|
Interventional |
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
- Pfizer
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Antitumor activity of crizotinib
- Safety (reporting of adverse events according to CTCAE v4.0)
- Progression free survival
- (and 4 more...)
|
582 |
All |
1 Year and older (Child, Adult, Senior) |
NCT01524926 |
EORTC-90101
2011-001988-52 |
CREATE |
September 2012 |
December 6, 2017 |
December 2018 |
February 2, 2012 |
January 23, 2018 |
|
- Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium - U.Z. Gasthuisberg
Leuven, Belgium - Institut Bergonie
Bordeaux, France - (and 22 more...)
|
| 17 |
NCT02837991 |
Recruiting |
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma |
- Renal Cell Carcinoma (RCC)
- Clear-cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- (and 3 more...)
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Escalation - Determine Maximum Tolerated Dose (MTD)
- Cohort Expansion - Assess Objective Response Rate (ORR)
|
125 |
All |
18 Years and older (Adult, Senior) |
NCT02837991 |
CDX014-01 |
|
June 2016 |
April 2019 |
August 2020 |
July 20, 2016 |
January 23, 2018 |
|
- HonorHealth Research Institute
Scottsdale, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 2 more...)
|
| 18 |
NCT00005799 |
Active, not recruiting |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 42 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- (and 7 more...)
|
Interventional |
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Establishment of an allograft as defined by stable mixed chimerism or full donor chimerism
- Disease-free survival
- Relapse
- (and 9 more...)
|
55 |
All |
Child, Adult, Senior |
NCT00005799 |
1463.00
NCI-2012-00667
P01CA018029
P30CA015704 |
|
November 1999 |
July 2002 |
|
April 2, 2004 |
October 11, 2017 |
|
- City of Hope Medical Center
Duarte, California, United States - Stanford University Hospitals and Clinics
Stanford, California, United States - University of Colorado
Denver, Colorado, United States - (and 4 more...)
|
| 19 |
NCT00078858 |
Active, not recruiting |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Acute Myeloid Leukemia in Remission
- (and 132 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
- (and 4 more...)
|
Interventional |
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of life-threatening GVHD in patients undergoing a modified taper of post-grafting immunosuppression after undergoing nonmyeloablative HSCT from matched unrelated donors
- Need for corticosteroid treatment, defined as more than 1 mg/kg or equivalent of prednisone for more than 3 days at any time after transplant
- Graft rejection
- (and 2 more...)
|
37 |
All |
Child, Adult, Senior |
NCT00078858 |
1668.00
NCI-2012-00668
P30CA015704
P01CA018029 |
|
September 2003 |
January 2006 |
|
March 9, 2004 |
February 27, 2018 |
|
- Stanford University Hospitals and Clinics
Stanford, California, United States - Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - (and 7 more...)
|
| 20 |
NCT00027820 |
Active, not recruiting |
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
- Adult Acute Myeloid Leukemia in Remission
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Acute Myeloid Leukemia in Remission
- (and 27 more...)
|
- Drug: Fludarabine Phosphate
- Radiation: Total-Body Irradiation
- Procedure: Peripheral Blood Stem Cell Transplantation
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Risk of true graft rejection in patients with and without preceding chemotherapy
- Risk of grades II-IV acute GVHD in those patients with sustained engraftment
- Incidence of reversing impending graft rejection (less than 40% donor cluster of differentiation [CD]3+ T cell chimerism)
- (and 2 more...)
|
106 |
All |
Child, Adult, Senior |
NCT00027820 |
1641.00
NCI-2012-00591
P30CA015704
P01CA018029 |
|
August 2001 |
September 2004 |
|
January 27, 2003 |
December 13, 2017 |
|
- University of Arizona Health Sciences Center
Tucson, Arizona, United States - Stanford University Hospitals and Clinics
Stanford, California, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - (and 7 more...)
|
| 21 |
NCT00126503 |
Completed
Has Results |
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer |
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- (and 3 more...)
|
- Biological: Bevacizumab
- Drug: Sorafenib Tosylate
- Other: Pharmacological Study
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I)
- Maximum Tolerated Dose of Bevacizumab in Combination With BAY 43-9006 (Sorafenib)(Phase I)
- Objective Response
- (and 2 more...)
|
73 |
All |
18 Years and older (Adult, Senior) |
NCT00126503 |
NCI-2009-00066
CDR0000434814
URO 470
6555
U01CA099177
P30CA068485 |
|
May 2005 |
October 2011 |
February 2012 |
August 4, 2005 |
January 15, 2015 |
June 28, 2013 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Dana-Farber Harvard Cancer Center
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 2 more...)
|
| 22 |
NCT01767636 |
Active, not recruiting |
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer |
- Carcinoma of the Collecting Ducts of Bellini
- Chromophobe Renal Cell Carcinoma
- Kidney Medullary Carcinoma
- (and 6 more...)
|
- Drug: Pazopanib Hydrochloride
|
Interventional |
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival rate
- Adverse event rate, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression-free survival
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT01767636 |
MC1152
NCI-2012-02027
P30CA015083 |
|
May 16, 2013 |
May 16, 2018 |
May 16, 2018 |
January 14, 2013 |
February 5, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
| 23 |
NCT00335556 |
Completed
Has Results |
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors |
- Childhood Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Clear Cell Sarcoma of the Kidney
- (and 10 more...)
|
- Drug: Doxorubicin Hydrochloride
- Drug: Irinotecan Hydrochloride
- Procedure: Conventional Surgery
- (and 7 more...)
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)
- Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors
- Response Rate
- (and 4 more...)
|
291 |
All |
up to 29 Years (Child, Adult) |
NCT00335556 |
AREN0321
NCI-2009-00414
COG-AREN0321
CDR0000472893
U10CA098543 |
|
June 2006 |
December 2015 |
|
June 12, 2006 |
July 21, 2017 |
June 14, 2017 |
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 184 more...)
|
| 24 |
NCT00276614 |
Completed
Has Results |
Bortezomib in Treating Patients With Metastatic Kidney Cancer |
|
|
Interventional |
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT00276614 |
CDR0000453541
P30CA016042
UCLA-0412011-01
MILLENNIUM-X05145 |
|
April 2006 |
July 2009 |
July 2009 |
January 13, 2006 |
November 24, 2015 |
April 19, 2012 |
- Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States
|
| 25 |
NCT00401128 |
Completed |
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer |
|
- Drug: gemcitabine hydrochloride
- Drug: irinotecan hydrochloride
|
Interventional |
Phase 2 |
- The Cleveland Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response
- Safety and efficacy
- Difference in response to therapy in patients with clear vs nonclear cell renal cell carcinoma
|
9 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00401128 |
CASE-CCF-6695
P30CA043703 |
|
May 2004 |
February 2007 |
February 2007 |
November 17, 2006 |
April 20, 2017 |
|
- Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 26 |
NCT00323791 |
Terminated |
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer |
|
- Drug: gemcitabine hydrochloride
- Drug: imatinib mesylate
- Genetic: gene expression analysis
- (and 3 more...)
|
Interventional |
Phase 2 |
- University of Medicine and Dentistry of New Jersey
- National Cancer Institute (NCI)
- Rutgers, The State University of New Jersey
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
- Stable disease
- Objective response
- Median survival
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT00323791 |
CDR0000539400
P30CA072720
CINJ-080507
CINJ-5633
CINJ-NJ3805 |
|
April 2006 |
August 2007 |
August 2007 |
May 10, 2006 |
December 11, 2009 |
|
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
|
| 27 |
NCT00459979 |
Completed
Has Results |
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery |
|
- Drug: sunitinib malate
- Procedure: conventional surgery
|
Interventional |
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response to Sunitinib Therapy
- The Number of Patients With Any Type of Complication or Adverse Event
- Progression Free Survival
- (and 4 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT00459979 |
CASE17806
P30CA043703
CASE-17806
CASE-17806-CC209 |
|
March 2007 |
March 2011 |
September 2013 |
April 13, 2007 |
March 7, 2014 |
January 7, 2014 |
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 28 |
NCT00027573 |
Completed |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer |
|
- Biological: filgrastim
- Biological: therapeutic allogeneic lymphocytes
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Overall survival
- Disease-free survival
- (and 2 more...)
|
36 |
All |
up to 60 Years (Child, Adult) |
NCT00027573 |
CALGB-90003
U10CA031946
CDR0000069044 |
|
October 2001 |
June 2006 |
June 2006 |
January 27, 2003 |
July 14, 2016 |
|
- CCOP - Mayo Clinic Scottsdale Oncology Program
Scottsdale, Arizona, United States - Indiana University Cancer Center
Indianapolis, Indiana, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 3 more...)
|
| 29 |
NCT01164228 |
Active, not recruiting |
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery |
|
- Drug: gemcitabine hydrochloride
- Drug: sunitinib malate
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Progression-free survival
- Overall survival
- Safety
|
100 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01164228 |
CDR0000681614
ECOG-E1808 |
|
June 17, 2010 |
May 31, 2018 |
May 31, 2023 |
July 16, 2010 |
December 14, 2017 |
|
- UAB Comprehensive Cancer Center
Birmingham, Alabama, United States - Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Stanford Cancer Center
Stanford, California, United States - (and 96 more...)
|
| 30 |
NCT01120249 |
Active, not recruiting |
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery |
|
- Drug: everolimus
- Other: placebo
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Compare Recurrence-free survival in those patients randomized to everolimus versus those randomized to placebo.
- Compare Overall survival in those patients randomized to everolimus versus those randomized to placebo.
- Compare Toxicity between the two study arms
|
1545 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01120249 |
S0931
U10CA032102
NCI-2011-02028 |
S0931 |
April 2011 |
October 2021 |
October 2021 |
May 10, 2010 |
December 8, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Gulf Coast MBCCOP
Mobile, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 1000 more...)
|
| 31 |
NCT00900536 |
Completed |
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE |
|
- Genetic: mutation analysis
- Genetic: polymorphism analysis
- Genetic: protein expression analysis
- (and 2 more...)
|
Observational |
|
- Medical Research Council
- National Cancer Institute (NCI)
|
Other |
|
- Relationship between tumor genotype, expression, and patient outcome
- Relationship between constitutional genotype and patient outcome
|
|
All |
18 Years and older (Adult, Senior) |
NCT00900536 |
MRC-RE05-TRANSORCE
CDR0000601175
EU-20867
EUDRACT-2006-006079-19
ISRCTN38934710 |
|
July 2007 |
|
June 2012 |
May 12, 2009 |
August 12, 2013 |
|
- Addenbrooke's Hospital
Cambridge, England, United Kingdom
|
| 32 |
NCT00492258 |
Completed |
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer |
|
- Drug: sorafenib tosylate
- Procedure: adjuvant therapy
|
Interventional |
Phase 3 |
- Medical Research Council
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival
- Metastasis-free survival
- Disease-specific survival time
- (and 3 more...)
|
1656 |
All |
18 Years and older (Adult, Senior) |
NCT00492258 |
MRC-RE05-SORCE
CDR0000553251
EUDRACT ID 2006-006079-19
EU-20734
ISRCTN38934710 |
|
June 2007 |
August 2012 |
December 2012 |
June 27, 2007 |
August 12, 2013 |
|
- Royal Bournemouth Hospital
Bournemouth, England, United Kingdom - Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom - Queen's Hospital
Burton-upon-Trent, England, United Kingdom - (and 36 more...)
|
Create an RSS feed from your search for:
Download the search results for: